441 related articles for article (PubMed ID: 31161258)
21. Multifunctional Desferrichrome Analogues as Versatile
Adams CJ; Wilson JJ; Boros E
Mol Pharm; 2017 Aug; 14(8):2831-2842. PubMed ID: 28665620
[TBL] [Abstract][Full Text] [Related]
22. Positron Emission Tomography Imaging of Platelet-Derived Growth Factor Receptor β in Colorectal Tumor Xenograft Using Zirconium-89 Labeled Dimeric Affibody Molecule.
Cai H; Shi Q; Tang Y; Chen L; Chen Y; Tao Z; Yang H; Xie F; Wu X; Liu N; Yang Y; Wu H; Tian R; Lu X; Li L
Mol Pharm; 2019 May; 16(5):1950-1957. PubMed ID: 30986347
[TBL] [Abstract][Full Text] [Related]
23. Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates.
Sarrett SM; Rodriguez C; Rymarczyk G; Hosny MM; Keinänen O; Delaney S; Thau S; Krantz BA; Zeglis BM
Bioconjug Chem; 2022 Sep; 33(9):1750-1760. PubMed ID: 35946495
[TBL] [Abstract][Full Text] [Related]
24.
Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
[TBL] [Abstract][Full Text] [Related]
25. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.
Holland JP; Divilov V; Bander NH; Smith-Jones PM; Larson SM; Lewis JS
J Nucl Med; 2010 Aug; 51(8):1293-300. PubMed ID: 20660376
[TBL] [Abstract][Full Text] [Related]
26. Trastuzumab-conjugated oxine-based ligand for [
Southcott L; Wharton L; Rousseau J; Merkens H; Yang H; Bénard F; Orvig C
J Inorg Biochem; 2022 Oct; 235():111936. PubMed ID: 35878576
[TBL] [Abstract][Full Text] [Related]
27. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and
Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM
Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334
[No Abstract] [Full Text] [Related]
28.
Fung K; Vivier D; Keinänen O; Sarbisheh EK; Price EW; Zeglis BM
Molecules; 2020 May; 25(10):. PubMed ID: 32429033
[TBL] [Abstract][Full Text] [Related]
29. Linear Desferrichrome-Linked Silicon-Rhodamine Antibody Conjugate Enables Targeted Multimodal Imaging of HER2 in Vitro and in Vivo.
Ahn SH; Thach D; Vaughn BA; Alford VM; Preston AN; Laughlin ST; Boros E
Mol Pharm; 2019 Mar; 16(3):1412-1420. PubMed ID: 30714739
[TBL] [Abstract][Full Text] [Related]
30. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
31. Site-Specific Photoaffinity Bioconjugation for the Creation of
Delaney S; Nagy Á; Karlström AE; Zeglis BM
Mol Imaging Biol; 2023 Dec; 25(6):1104-1114. PubMed ID: 37052759
[TBL] [Abstract][Full Text] [Related]
32.
Pandya DN; Bhatt NB; Almaguel F; Rideout-Danner S; Gage HD; Solingapuram Sai KK; Wadas TJ
J Nucl Med; 2019 May; 60(5):696-701. PubMed ID: 30442753
[No Abstract] [Full Text] [Related]
33. Advancing
Wuensche TE; Stergiou N; Mes I; Verlaan M; Schreurs M; Kooijman EJM; Janssen B; Windhorst AD; Jensen A; Asuni AA; Bang-Andersen B; Beaino W; Dongen GAMS; Vugts DJ
Theranostics; 2022; 12(16):7067-7079. PubMed ID: 36276653
[TBL] [Abstract][Full Text] [Related]
34. Cyclic versus Noncyclic Chelating Scaffold for
Summer D; Garousi J; Oroujeni M; Mitran B; Andersson KG; Vorobyeva A; Löfblom J; Orlova A; Tolmachev V; Decristoforo C
Mol Pharm; 2018 Jan; 15(1):175-185. PubMed ID: 29160082
[TBL] [Abstract][Full Text] [Related]
35. Total-Body PET and Highly Stable Chelators Together Enable Meaningful
Berg E; Gill H; Marik J; Ogasawara A; Williams S; van Dongen G; Vugts D; Cherry SR; Tarantal AF
J Nucl Med; 2020 Mar; 61(3):453-460. PubMed ID: 31562219
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody-Drug Conjugates.
Azhdarinia A; Voss J; Ghosh SC; Simien JA; Hernandez Vargas S; Cui J; Yu WA; Liu Q; Carmon KS
Mol Pharm; 2018 Jun; 15(6):2448-2454. PubMed ID: 29718672
[TBL] [Abstract][Full Text] [Related]
37. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for (89)Zr(4+) and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice.
N Tinianow J; Pandya DN; Pailloux SL; Ogasawara A; Vanderbilt AN; Gill HS; Williams SP; Wadas TJ; Magda D; Marik J
Theranostics; 2016; 6(4):511-21. PubMed ID: 26941844
[TBL] [Abstract][Full Text] [Related]
39. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
[TBL] [Abstract][Full Text] [Related]
40.
Heskamp S; Raavé R; Boerman O; Rijpkema M; Goncalves V; Denat F
Bioconjug Chem; 2017 Sep; 28(9):2211-2223. PubMed ID: 28767228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]